About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Tennessee | 20,239 Studies Near You | Clareo Health

Clinical Trials LocationsTennessee

Clinical Trials in Tennessee

Discover 20,239 clinical trials near Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4341-4360 of 20,239 trials

COMPLETEDPhase 218 miles

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

NCT04856917

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

Vanda Pharmaceuticals123 participantsStarted May 2021

Hot Springs, Arkansas, United States • Fountain Valley, California, United States • Sherman Oaks, California, United States +12 more locations

TERMINATEDPhase 129 miles

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

NCT05200364

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Ovarian CancerOvarian CarcinomaOvary Cancer+2 more

Sutro Biopharma, Inc.58 participantsStarted Mar 2022

Tampa, Florida, United States • Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States +3 more locations

Find Trials by Condition in Tennessee

Breast Cancerin Tennessee Lung Cancerin Tennessee Prostate Cancerin Tennessee Colorectal Cancerin Tennessee Melanomain Tennessee Leukemiain Tennessee Lymphomain Tennessee Pancreatic Cancerin Tennessee Ovarian Cancerin Tennessee Brain Cancerin Tennessee

Data from ClinicalTrials.govTerms

COMPLETEDPhase 429 miles

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

NCT03971071

Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

Migraine Headache

Amgen620 participantsStarted Oct 2019

Cerritos, California, United States • Colton, California, United States • Los Angeles, California, United States +91 more locations

Active Not Recruiting71 miles

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

NCT03289780

The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.

Non-Small Cell Lung Cancer

Biodesix, Inc.5,006 participantsStarted Apr 2016

Huntsville, Alabama, United States • Tuscaloosa, Alabama, United States • Fayetteville, Arkansas, United States +39 more locations

Active Not RecruitingPhase 3154 miles

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

NCT01503632

This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia that has had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes.

Acute Lymphoblastic Leukemia

Children's Oncology Group570 participantsStarted Feb 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Downey, California, United States +99 more locations

COMPLETEDPhase 3154 miles

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

Prostate Cancer

Blue Earth Diagnostics391 participantsStarted May 2020

Birmingham, Alabama, United States • Los Angeles, California, United States • Orange, California, United States +25 more locations

COMPLETEDPhase 2154 miles

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

NCT05079035

It is hypothesized that a single Intra-articular Injection of TTAX03, 100mg in 2mL of saline, will have more benefit with respect to the proportion of responders 12 weeks post-injection than an equal volume of saline, based on the OMERACT-OARSI responder criteria.

Knee OsteoarthritisKnee Pain ChronicKnee Arthritis

BioTissue Holdings, Inc90 participantsStarted Dec 2021

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +7 more locations

COMPLETEDPhase 3156 miles

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

Type 2 Diabetes

Eli Lilly and Company1,698 participantsStarted Sep 2023

Phoenix, Arizona, United States • Canoga Park, California, United States • Escondido, California, United States +128 more locations

RECRUITINGPhase 2190 miles

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128

The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.

Irritable Bowel Syndrome

AbbVie95 participantsStarted Nov 2017

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • Corona, California, United States +43 more locations

Active Not Recruiting250 miles

Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

NCT04171492

This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.

Nodule Solitary PulmonaryNon-small Cell Carcinoma

Biodesix, Inc.2,000 participantsStarted Dec 2020

Aurora, Colorado, United States • Boston, Connecticut, United States • Boston, Connecticut, United States +22 more locations

COMPLETED262 miles

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

NCT03597399

The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.

Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

Spark Therapeutics, Inc.87 participantsStarted Jan 2019

Los Angeles, California, United States • Miami, Florida, United States • Iowa City, Iowa, United States +7 more locations

Active Not Recruiting277 miles

Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative

NCT03910933

Effective patient education improves health literacy and engagement thus improving long-term health outcomes. Health literacy is imperative to make informed health decisions and relies on the ability to obtain, process and understand health information; and is the cornerstone of safe health management. It is necessary to evaluate educational initiatives to determine their effectiveness in knowledge translation. A more effective way to provide patient education is to utilize media technology. Current education styles do not teach patients in the best way as they are not consistent with how people of all ages currently learn (through technology). In addition, patient teaching most commonly occurs during highly stressful times like hospital visits with new diagnoses. Current patient educational methods are costly given the amount of health provider time required. Electronic KITE teaching modules are infographic visual representations that present information quickly and clearly, integrating words and graphics to tell a story to reveal information. Infographic presentations are tools which facilitate self-directed learning with understandable, accessible information presented in an engaging way with an aim to enhance learning for children and their families. Patients are able to learn at a pace consistent with their learning style to facilitate knowledge development and health literacy.

Health LiteracyAnticoagulation

University of Alberta248 participantsStarted Jun 2017

Chicago, Illinois, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +3 more locations

COMPLETEDPhase 3311 miles

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00371033

The purpose of this study is to determine whether pregabalin is an effective treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)324 participantsStarted Mar 2006

Los Angeles, California, United States • Los Angeles, California, United States • Stanford, California, United States +8 more locations

Active Not RecruitingPhase 1425 miles

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372

The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.

Novartis Pharmaceuticals137 participantsStarted Oct 2021

Los Angeles, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +13 more locations

Active Not RecruitingEARLY Phase 1437 miles

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707

The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. Fluoxetine, a drug approved by the FDA to treat problems like depression and anxiety, can cause changes to structures in cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain.

Primary Brain TumorBrain Tumor, Recurrent

Duke University10 participantsStarted Aug 2023

San Diego, California, United States • Stanford, California, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 1455 miles

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

NCT04223752

This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).

Nosocomial Pneumonia

Merck Sharp & Dohme LLC41 participantsStarted Apr 2020

Orlando, Florida, United States • Rochester, Minnesota, United States • New York, New York, United States +21 more locations

COMPLETED480 miles

EchoTip AcuCore Post-Market Clinical Study

NCT06358001

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

AdenocarcinomaNeuroendocrine TumorsHepatocellular Carcinoma+5 more

Cook Research Incorporated183 participantsStarted Aug 2024

Orange, California, United States • Denver, Colorado, United States • Gainesville, Florida, United States +5 more locations

Active Not RecruitingPhase 2/3961 miles

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

NCT05766267

The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week. The first 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) (BMZRB) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb) (2 BMZRb/2 BMRb, Arm 1) The Second 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus delamanid (D or DLM); (BMZD) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD, Arm 2) The standard 26-week treatment control regimen which is two months of isoniazid, rifampin, ethambutol, and pyrazinamide (2HRZE) followed by four months of isoniazid and rifampin (4HR); (2HRZE/4HR, Arm 3) Target enrollment is 288 male and female participants (96/arm). participants. Participants will be followed until 78 weeks post-randomization, or until the last enrolled participant completes 52 weeks post-randomization, whichever comes first.

Tuberculosis, PulmonaryTuberculosis Infection

Centers for Disease Control and Prevention288 participantsStarted Nov 2023

Seattle, Washington, United States • Montreal, Canada • Vancouver, Canada +5 more locations

RECRUITING1285 miles

Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)

NCT05534009

The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).

Euresist Network GEIE1,800 participantsStarted Apr 2022

Düsseldorf, Germany • Milan, Italy • Milan, Italy +4 more locations

RECRUITING1285 miles

Post COVID-19 Condition

NCT05531773

The EuCARE-POSTCOVID study is an observational multicentre study enrolling COVID-19 patients recovered from the acute phase of disease to investigate the prevalence and possible predictors of post COVID-19 condition. The study will retrospectively analyze data already collected at the post COVID-19 outpatients services of the participating centers; furthermore, a prospective cohort study will be performed.

Euresist Network GEIE2,300 participantsStarted Jul 2022

Düsseldorf, Germany • Rome, Lazio, Italy • Milan, Lombardy, Italy +4 more locations

PreviousPage 218 of 1012Next

Diabetes

in Tennessee

Heart Diseasein Tennessee